Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Market Exclusivity for 'novel' biological drug products

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Jun 05, 2023 10:29am

118 Views

Post# 35480292

RE:RE:Market Exclusivity for 'novel' biological drug products

yup, but like you state, they need approval first..!

So from 2028, another entity could combines pela + their own CPI, have a biomarker in place, and if they were to beat ONCY to the finish line... well, they would have the exclusivity..

lol... too funny really...

<< Previous

Bullboard Posts

Next >>

AI companies to invest in